record million, second Revenue afternoon, good in a totaled of second new for XXXX in over quarter the our and company. quarterly increase XXXX XX% the Raj, you, an quarter of everyone. Thank $XX.X
strong details our of our foundation moment. which a the We are a there markets, build performance to for is all coming on beyond. months, of excess we Raj number well outlook of on in over underlying second catalysts provide providing XXXX a positive and additional quarter are our in and growing which expect will and
the our of public the our campus. July listing Sulayom On as company, anniversary innovation we of opening XX, a grand held X-year
XXX attended Rican Costa event, government, of For other surgeons, the and representatives from including partners. around suppliers the people world, the distributors plastic business
supports R&D, and XX,XXX The manufacturing our training over approximately X.X capacity year, manufacturing, in plans and current we new million capacity education. year, about capabilities campus that new of This our of additional warehouse digital to doubles is feet than and global media, strategic bring medical units manufacturing will the demand. a more space with online square half which
our the add to have additional requires. of feet XX,XXX growth also ability manufacturing square We an as
that world. new to allows content demand market surgical medical broad allow the expand and our us education business for learning and include help on-site The center that produce a can facilities around and that for and us theater to The the our stream and can R&D scale create global global advanced labs products. we rooms training procedure
and neutral be other sustainable is uses design art facility in throughout. and carbon elements State-of-the designed to green standards materials
for are goal care opening can and the succeeded. of certain professionals with was where surgery. Our a and creation And from all Sulayom, center over new to the innovation, our employees, we partners usher build for have standards the plastic health we future world of the
the world. and have a to ever we new than make create the lives and of expand women been positioned better to around change are in We meaningful markets
exciting near-term us the is of Mia most opportunities for Femtech. One
in picking the this approval global up breast is With of of in the pace. category recent Europe rollout needed, the tools new aesthetics
new centered certified of list clinics. partner are activities Our launch creating with growing category, these on our
Costa Rica with in centers We to clinics Germany, more England, every partner join. of requests Japan, Switzerland, pipeline and are new France, with our Sweden, strengthening week Spain,
have We saw XX% patient-seeking demand. first we creating a consumer of which Spain, were that market appointments. resulted and marketing XXX over launched of directed about Most where augmentation in at prior each us and not generate breast XX programs capturing the for in these seeking Mia. In week July, are leads, localized our learning created branding patients first to campaign importantly,
discrete better overcomes many As for of plastic surgeons of X to X in to shape into new are with XX-minute the The a still of Mia group cup launch benefiting proportionate focused economics. general breast aesthetics. whole this on experience, is providing we procedure the need women clinics from result. a By a in is of anesthesia. up plastic day. see part opening obstacles It to and procedure same the women can we of traditional reminder, requires bringing as as early partner breast most that category activities Mia, our solution the The a without efficiency returning women downtime breast remain a the surgeon breast augmentation, with invasive minimally result aesthetics the new growing minimal of with a improved
that are into opportunity. dollar new can proof points this multibillion seeing we scale a We early Mia category with
before Flora the allows breast the oncology used our during which is We port, improvements the new with rollout devices better X improved have little offer our women Despite expander for in developing healthy who breast capsule aesthetic and can technology, By franchise, tissue recon in of meaningful women imaging comfort SmoothSilk also Flora the patented time MRI our expanders continues. surface developed are tissue which seen RFID-enabled Flora In [indiscernible] formation. being our expander decades. for patient provide features opens Flora surgeons a options. innovation a artifacts receive cancer, in Flora mastectomy. and to non-magnetic, also self-friendly after Flora Motiva X radiation and first-of-its-kind these treatment. a options Among
image not improvement quality out that fundamental sequences of with during very for study feedback confirm Switzerland publication positive, does prone expanders. recent women image an reconstruction confirming a MRI, breast the was artifact seeing in-human of number market the of we undergoing tissue the in Flora. clinical care are publications of first The is and standard A increasing benefits the to of Flora affect
The lungs Motiva to the out recent compared Flora, the to that on RFID-enabled conventional in also traditional showed expanders. results materials non-metallic to CT versus and metals effects reducing Their port, in heart demonstrated with the organs. Korea South radiotherapy metallic of dosimetric used RFID publication side port reduce the artifacts superior these potentially imaging planning ports,
scientists in study journeys their a compared and to that University reconstruction Austria, in provides Business we another Flora the to able published FDA-approved In breast recently an paper, in head-to-head much of at comfort satisfaction Medical confirm patient expander. Work are improved
reconstruction. to As is they tools health, our company responsibility women only in has the will that breast first step to techniques Establishment the global initiative, opportunity the aesthetic focused device a offer and medical allow the surgeries improve recon where Labs achieve on that breast and receive to aesthetic aspire. women’s Establishment which reconstructive Flora Labs ideals
are for partner. with of we our Motiva preparing China, launch distribution the On actively
We in continue to progress regulatory market launch this make this to the Motiva later process expect in year. and
agency. of questions It the is under the In to our the communication partners U.S., final the submitted PMA in the and in module review been has PMA final first by FDA the close China active the before approval. was to remaining been quarter, have accepted. full with regulatory in the We now
in will remain Clinical undergone regulatory process of around closer have country thus the the activity there and bringing with pace process our the nothing us to women in via The positive. sites be difficult lines, United the but this Implants our agency It confidence time predict States. Motiva in approval. soon interactions has diminished is inspections, now that far available of to
now over call the Raj. I will turning to
